NAACCR Item #3941: NRAS Mutational Analysis
| Item # | Length | Source of Standard | Year Implemented | Version Implemented | Year Retired | Version Retired |
|---|---|---|---|---|---|---|
| 3,941 | 1 | NAACCR | 2021 | 21 |
NAACCR XML: Tumor.nrasMutationalAnalysis
Description
NRAS is a signaling intermediate in the growth receptor pathway. Certain NRAS mutations predict poor response to anti-EGFR therapy in patients with metastatic colorectal cancer.
Rationale
NRAS mutational analysis is recommended in clinical guidelines for patients with metastatic colon cancer who are being considered for anti-EGFR therapy. It is a new data item for cases diagnosed 01/01/2021+.
Codes
| 0 | Normal NRAS negative; NRAS wild type Negative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected |
| 1 | Abnormal (mutated)/detected in codon(s) 12, 13, and/or 61 |
| 2 | Abnormal (mutated)/detected, codon(s) specified but not in codon(s) 12, 13, or 61 |
| 4 | Abnormal (mutated), NOS, codon(s) not specified |
| 7 | Test ordered, results not in chart |
| 8 | Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error. |
| 9 | Not documented in medical record NRAS not assessed or unknown if assessed |
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.